ANALYZING THE QUALITY OF LIFE OF HEPATITIS C PATIENTS. LITERATURE REVIEW
Authors/Creators
Description
Abstract
A literature review was conducted on the study of quality of life in patients with hepatitis C in global clinical practice based on data published to date. Viral hepatitis C is a serious global health problem that affects millions of people worldwide. In addition to physical symptoms, the disease can significantly affect the overall well-being and quality of life of patients. A number of studies are now available to shed light on various aspects of hepatitis C patients’ lives that affect their physical health, psychological well-being and life satisfaction. The key point emphasized by most researchers is the need for a comprehensive approach to the treatment of patients, focusing not only on virus elimination, physical aspects of the disease, but also on adequate emotional support, disease awareness and the possibility of social integration to mitigate the negative impact on people’s quality of life. Therefore, assessment of long-term quality of life in patients with hepatitis C at different stages of treatment and after virus elimination remains relevant at present.
Other
References:
1. World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Available at: https://www.who.int/publications/i/item/9789240027077
2. Kozhevnikova G.M., Alikeeva G.K., Shamov A.S., Yushchuk N.D. Risk factors for contracting viral hepatitis in drug users. Epidemiology and infectious diseases. 1998; 3:47-48.
3. Sukhoruk A.A. abstract. Determination of tactics for managing patients with chronic hepatitis C with outcome in liver cirrhosis based on their clinical and laboratory characteristics, 2015.
4. Pimenov N.N. abstract. Current manifestations of the hepatitis C epidemic process in Russia and ways to improve epidemiological surveillance, 2019.
5. Gower, E. Global epidemiology and genotype distribution of the hepatitis C virus infection / E. Gower, C. Estes, S. Blach, K. Razavi-Shearer, H. Razavi // Journal of Hepatology. - 2014. - V.61. - P. 45-57.
6. Viral hepatitis in the Russian Federation. Analytical review. Ed. Pokrovsky V.I., Zhebrun A.B. St. Petersburg; 2013.
7. Enaleeva D. Sh., Fazylov V. Kh., Sozinov A. S. Chronic viral hepatitis B, C and D: a guide for doctors. V.: GEOTAR-Media; 2015. 192 p.
8. Younossi Z.M., Boparai N., Price L.L., et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001; 96 (7):2199-205. DOI: 10.1111/j.1572-0241.2001.03956.x
9. Baygaliev A.A. Pavlodar branch of State Medical University of Semey, Kazakhstan. Study of the quality of life in patients with chronic hepatitis C, 2010
10. Golubeva M. D., Dorofeeva K. V. Assessing the impact of chronic liver diseases on the presence of fatigue in patients, 2020.
11. Ishinuki T., Ota S., Harada K., Kawamoto M., Meguro M., Kutomi G., Tatsumi H., Harada K., Miyanishi K., Kato T., Ohyanagi T., Hui T.T., Mizuguchi T. Current standard values of health utility scores for evaluating cost-effectiveness in liver disease: A meta-analysis. World J Gastroenterol. 2022 Aug 21; 28(31):4442-4455. doi: 10.3748/wjg.v28.i31.4442. PMID: 36159009; PMCID: PMC9453766.
12. Importance of fatigue and its measurement in chronic liver disease / Gerber L. H., Younossi Z.M. [et al.] // World J Gastroenterol. – 2019. – Vol. 25 (28). – P. 3669-3683.
13. Rozina V.L., Sitnikov I.G., Bokhonov M.S. Changes in the quality of life of patients during combined antiviral therapy for chronic hepatitis C //Children’s infections. 2019 - 18 (4). - P. 38-42.
14. Horváth G. et al. Effect of hepatitis C infection on the quality of life //Perspectives in psychiatric care. 2018; 54 (3). - P. 386–390.
15. Jean-Michel Pawlotsky, Christian B. Ramers, John F. Dillon, Jordan J. Feld, Jeffrey V. Lazarus - Simplification of Care for Chronic Hepatitis C Virus Infection. Semin Liver Dis. 2020 Nov; 40(4):392-402. doi: 10.1055/s-0040-1713657. Epub 2020 Jul 28.
16. Josep Mallolas, Adriana Ahumada, Javier Ampuero, José Ramón Blanco, Álvaro Hidalgo, Maria-Carlota Londoño, Esther Molina, Salvador Ruiz - Quality of life in patients with hepatitis C. Importance of treatment. Gastroenterol Hepatol. 2019 Sep; 42 Suppl 1:20-25.
17. Maksimova L.V., Vorobyov P.A. Determination of the quality of life of patients with chronic hepatitis B (C) using the euroqol 5d questionnaire. - Problems of standardization in healthcare, 5-6, 2013
18. Honrubia López R., Madejón Seiz A., Romero Portales M., García Sánchez A., Castillo Grau P., Erdozain Sosa J.C., Olveira Martín A., Robles A., García-Samaniego Rey J. Quality of life study in asymptomatic patients with hepatitis C. Rev Esp Enferm Dig. 2020 Jul;112(7):520-524. doi: 10.17235/reed.2019.6339/2019. PMID: 31617364.
19. GoñiEsarte S, Juanbeltz R, Martínez-Baz I, Castilla J, San Miguel R, Herrero JI, Zozaya JM. Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents. Rev EspEnferm Dig. 2019 Jun;111(6):445-452. doi: 10.17235/reed.2019.6063/2018. PMID: 31066286.
20. Juanbeltz R, Martínez-Baz I, San Miguel R, et al. Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS One 2018;13(10):e0205277. DOI:10.1371/journal.pone.0205277
21. Marcellin F, Roux P, Protopopescu C, et al. Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Rev Gastroenterol Hepatol 2017;11(3):259-68. DOI: 10.1080/17474124.2017.1285227
22. Wong WWL, Wong J, Bremner KE, Saeed Y, Mason K, Phoon A, Martel-Laferrière V, Bruneau J, Feld JJ, Feng Z, Baguley E, Lee SS, Powis J, Krahn MD. Impact of direct-acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings. Liver Int. 2023 Apr;43(4):805-818. doi: 10.1111/liv.15518. Epub 2023 Feb 5. PMID: 36606706.
23. Kaminskaya S. N. Clinical and psychological characteristics and quality of life of patients with chronic viral hepatitis C, 2014.
24. Atamla M., Khoury J., Dabbah I., Kramsky R., Yaacob A., Veitsman E., Saadi T. Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term. Clin Exp Hepatol. 2021 Sep; 7(3):258-263. doi: 10.5114/ceh.2021.109192. Epub 2021 Sep 20. PMID: 34712826; PMCID: PMC8527337.
25. van der Plas S.M., Hansen B.E., de Boer J.B., Stijnen T., Passchier J., de Man R.A., Schalm S.W. The Liver Disease Symptom Index 2.0; validation of a disease-specific questionnaire. Qual Life Res. 2004 Oct; 13(8):1469-81. doi: 10.1023/B:QURE.0000040797.17449.c0. PMID: 15503842.
26. Youssef N.F., El Kassas M., Farag A., Shepherd A. Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt. BMC Gastroenterol. 2017 Jan 21; 17(1):18. doi: 10.1186/s12876-017-0581-1. PMID: 28109264; PMCID: PMC5251342
27. Akio Miyasaka, Yuichi Yoshida, Akiko Suzuki, Yasuhiro Takikawa - Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response. 2021 Dec; 30(12):3501-3509. doi: 10.1007/s11136-021-02874-6. Epub 2021 May 19.
28. Silvia Nardelli, Oliviero Riggio, Davide Rosati, Stefania Gioia, Alessio Farcomeni, Lorenzo Ridola - Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms. World J Gastroenterol. 2019 Dec 28; 25(48): 6928–6938
29. Suzuki M., Ishikawa T., Sakuma A., Abe S., Abe H., Koyama F., et al. Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment. Exp Ther Med. 2016; 12:3353–3358.
30. Shahid I., AL Malki W.H., Hafeez M.H., Hassan S. Hepatitis C virus infection treatment: an era of game changer direct acting antivirals and novel treatment strategies. CritRevMicrobiol. 2016; 42:535–547.
31. Perlin C.M., Ferreira V.L., Borba H.H., Wiens A., Ivantes C.A., Lenzi L., et al. Quality of life in Brazilian patients with treated or untreated chronic hepatitis C. Rev Inst Med Trop Sao Paulo. 2017; 59:e81
32. Ng X., Nwankwo C., Arduino J.M., Corman S., Lasch K.E., Lustrino J.M., Patel S., Platt H.L., Qiu J., Sperl J. Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir. Patient Prefer Adherence. 2018; 12:2631–2638
33. Siqueira F.M., Ferreira V.L., Borba H.H.L., Pontarolo R. Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies. Rev Inst Med Trop Sao Paulo. 2018; 60:e72.
34. Fagundes R.N., Ferreira L.E.V.V.C., Pace F.H.L. Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free. PLoS One. 2020 Aug 19; 15(8):e0237005. doi: 10.1371/journal.pone.0237005. PMID: 32813740; PMCID: PMC7437906.
35. Younossi Z.M., Racila A., Muir A., Bourliere M., Mangia A., Esteban R., Zeuzem S., Colombo M., Manns M., Papatheodoridis G.V., Buti M., Chokkalingam A., Gaggar A., Nader F., Younossi I., Henry L., Stepanova M. Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. Clin Gastroenterol Hepatol. 2022 Feb;20(2):438-446. doi: 10.1016/j.cgh.2021.01.026. Epub 2021 Jan 22. PMID: 33493697.
36. Jean-Michel Pawlotsky, Christian B Ramers, John F. Dillon, Jordan J. Feld, Jeffrey V. Lazarus - Simplification of Care for Chronic Hepatitis C Virus Infection. Semin Liver Dis. 2020 Nov; 40(4):392-402. doi: 10.1055/s-0040-1713657. Epub 2020 Jul 28.
37. Ohlendorf V., Schäfer A., Christensen S., Heyne R., Naumann U., Link R., Herold C., Schiffelholz W., Günther R., Cornberg M., Serfert Y., Maasoumy B., Wedemeyer H., Kraus M.R. Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). J Viral Hepat. 2021 Aug; 28(8):1206-1218. doi: 10.1111/jvh.13546. Epub 2021 Jun 8. PMID: 34003549.
38. Marcellin F., Roux P., Protopopescu C., Duracinsky M., Spire B., Carrieri M.P. Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert RevGastroenterolHepatol. 2017 Mar; 11(3):259-268. doi: 10.1080/17474124.2017.1285227. Epub 2017 Jan 31. PMID: 28116926.
39. Kracht P.A.M., Lieveld F.I., Amelung L.M., et al. The impact of hepatitis C virus direct-acting antivirals on patient-reported outcomes: A Dutch prospective cohort study. Infect Dis Ther. 2018; 7:373-385.
40. Vyas B.H., Darji N.H., Rana D.A., Vyas K.Y., Malhotra S.D. Impact of newer direct-acting antiviral drugs based on quality-adjusted life years: A prospective pharmacoeconomic study in hepatitis C patients. Perspect Clin Res. 2021 Apr-Jun; 12(2):76-82. doi: 10.4103/picr.PICR_123_19. Epub 2020 May 7. PMID: 34012903; PMCID: PMC8112329.
Files
IISJ_58-21-28.pdf
Files
(737.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:02339314af312882338546e3f9544238
|
737.0 kB | Preview Download |